Connect
← Return to Anyone living with Essential Thrombocythemia with JAK2?
Discussion
Anyone living with Essential Thrombocythemia with JAK2?
Blood Cancers & Disorders | Last Active: 5 hours ago | Replies (676)Comment receiving replies
Interesting bit of news for ET patients: Yesterday, 8/31/26, The FDA approved Besremi for the treatment of Essential Thrombocythemia (ET). It improves not only the platelets levels (in some patients by 56%), it also decreased the JAK2 mutation burden, actually modifying the disease.
Several article links:
Onco Daily https://oncodaily.com/hematology/besremi-essential-thrombocythemia578363
Health Tree:
https://healthtree.org/mastocytosis/news/08-31-2026-fda-besremi-approval-for-et
This is the first new drug approval for ET in 30 years. For some patients this may have the potential for durable remission. HU can help keep the platelet levels lower but it doesn’t impact the JAK2 mutation. This may be something to talk over with your hematologists. Feed back from ET members?
Replies to "Interesting bit of news for ET patients: Yesterday, 8/31/26, The FDA approved Besremi for the treatment..."
@loribmt
Thanks for sharing this news, Lori! To have another approved treatment option for ET after 30 years has to be some good news, especially for those for whom their current treatment isn't working.
I noticed in the study that the participants were chosen from those for whom hydroxyurea was no longer working or tolerated. The linked articles and the links in them were very informative.
@loribmt it sounds like the approval is pretty broad? Maybe more people will be able to access it? Or do patients have to fail on HU first?
Connect
@loribmt thanks for sharing, I will be talking my HU on my next visit. Jennifer